Fluorescent In Situ Hybridization Probe Market Strengthened by Biotech Funding

The global fluorescent in situ hybridization (FISH) probe market size was estimated at USD 951.77 million in 2024 and is projected to reach USD 1,485.88 million by 2030, at a compound annual growth rate (CAGR) of 7.78 % from 2025 to 2030. The growth is driven by rising incidences of genetic disorders and cancer, technological advancements in molecular diagnostics, and an expanding clinical research and drug-development landscape.

Key Market Trends & Insights

• In 2024, the North American region dominated the market, holding a 44.33 % share.
• The U.S. in particular leads, bolstered by high cancer incidence and robust research-and-development activity.
• By technology, the FLOW-FISH segment held the largest share in 2024—about 35.81 % of the market—and is reported to be the fastest growing segment over the forecast period.
• In terms of probe type, DNA probes represent the largest segment with a 55.85 % revenue share in 2024 (RNA-probes are emerging fastest).
• By application, cancer diagnostics accounts for the largest revenue share with 43.85 % in 2024.
• For end-use, the clinical-use segment led with 41.33 % share in 2024.

Market Size & Forecast

• Looking at the forecast: the 2024 base size is USD 951.77 million; the 2030 projected size is USD 1,485.88 million; and the CAGR from 2025 to 2030 is 7.78%.
• Growth is supported by increasing demand for precision diagnostics, the rising prevalence of genetic and oncologic diseases, and expanding adoption of multiplex, automated, and high-throughput FISH probe technologies.
• Regional expansion in Asia Pacific, Latin America and MEA is also playing a role; Asia-Pacific is noted as the fastest growing region, driven by increased healthcare infrastructure, awareness and government investments.

Order a free sample PDF of the Fluorescent In Situ Hybridization Probe Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

The market features significant innovation, especially in probe specificity, multiplexing capabilities, automation, and integration with other genomic platforms.

Mergers and acquisitions are frequent, as major players aim to acquire proprietary probe technologies, expand portfolios and enter new geographic markets.

The regulatory environment is a key factor: clinical diagnostic FISH probes must comply with stringent standards (such as FDA in the U.S. and CE in Europe), which adds to development cost and approval time—but also supports adoption by enhancing trust in clinical use.

While large, well-established firms currently dominate, smaller and regional players are entering with niche or cost-effective solutions, putting competitive pressure on incumbents.

Key Companies List

Prominent companies in the FISH probe market include:

• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioDot
• Horizon Diagnostics
• Agilent Technologies, Inc.
• Abnova Corporation
• LGC Biosearch Technologies
• Genemed Biotechnologies, Inc.
• Oxford Gene Technology IP Limited
• Biocare Medical, LLC
• QIAGEN (Exiqon A/S)
• GSP Research Institute, Inc.

Conclusion

The FISH probe market is poised for notable expansion through to 2030, underpinned by growing demand for advanced molecular diagnostics across cancer and genetic disease applications, and by the rise of sophisticated technologies such as FLOW-FISH, multiplexed probes and automation. North America currently leads from a revenue perspective, while Asia-Pacific emerges as a high-growth frontier. DNA-based probes and cancer diagnostics presently dominate the segment, and the clinical end-use channel remains the largest driver. With a competitive landscape dominated by large global players yet dynamically challenged by agile newcomers and regional specialists, success will depend on continuous innovation, regulatory compliance, automation and regional market penetration.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.